TELL : +91 0 99 08 87 07 06

 Mcmed International ®: Largest Journal Publication in world

Acta Biomedica Scientia

Volume 6, Issue 3, 2019
Mcmed International
Acta Biomedica Scientia
Issn
2348 - 215X (Print), 2348 - 2168 (Online)
Frequency
bi-annual
Email
editorabs@mcmed.us
Journal Home page
http://mcmed.us/journal/abs
Recommend to
A Friend  | A librarian
Purchase
Purchase Issue
Abstract
Title
EFFECTIVENESS FOR SEIZURES WITH RESPECT TO OXYCARBAZEPINE AND PHENYTOIN MONOTHERAPY
Author
Dr.Gundam Murali Mohan Reddy1* & Dr.M.Nagaraj2
Email
Mohan Reddy@gmail.com
keyword
seizures, oxycarbazepine, phenytoin, monotherapy
Abstract
Oxcarbazepine is a relatively new antiepileptic medication with molecular features similar to its parent molecule carbamazepine. This is approved for usage in a range of nations as a monotherapy but as an add-on therapy. The research of oxcarbazepine as a treatment for persons with partial start-up epilepsy provides strong evidence that, when administered as a placebo supplement, oxcarbazepine reduces the occurrence of seizures. We are aimed to compare oxcarbazepine and phenytoin in participants with partial onset seizures or generalized tonic-clonic seizures with or without other generalized seizure forms as used as monotherapy. The results of this trial suggest that oxcarbazepine might be preferable than phenytoin as an initial monotherapy for people with partial epilepsy. More evidence than oxcarbazepines in relation to other standard antiepileptic drugs would be necessary to make an informed judgement across all possibilities. At present, carbamazepine is utilised as a first-line treatment in accordance with the guidelines for partial epilepsy.
Download Broucher
Back to Top >>>>